Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. (BSGM) on September 2, 2020. The report details a material definitive agreement entered into by ViralClear Pharmaceuticals, Inc., a majority-owned subsidiary of BioSig. ViralClear is the successor-in-interest to Trek Therapeutics, PBC and is developing Merimepodib for the treatment of COVID-19.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The financial impact is described through the restructuring of milestone payments and royalty rates within a licensing agreement with Vertex Pharmaceuticals Incorporated.
Material Changes
The primary material change is the execution of a second amendment to an assignment and license agreement with Vertex Pharmaceuticals. Key modifications include:
- Entity Name Change: All references to "TREKtx" in the agreement are updated to "ViralClear."
- Milestone Reduction: The first two milestone events (initiation of Phase 2 and Phase 3 clinical trials in non-HCV indications) and their associated payments totaling $6 million have been eliminated.
- Royalty Increase: The running royalties rate has been increased from 5% to 6%.
- Remaining Milestones: The amended agreement now contains only two milestone events and associated payments.
Outlook and Management Commentary
Management states that the amendment enables ViralClear to execute on its program for COVID-19. The removal of specific non-HCV milestone payments and the adjustment of royalty terms are intended to align the agreement with the current development focus on Merimepodib for COVID-19 treatment. No specific financial guidance or risk factors beyond the standard incorporation of the agreement text are provided in this summary.
Investor Verification Checklist
- Verify the full text of Amendment No. 2 (Exhibit 10.1) to confirm the specific terms of the remaining two milestone events.
- Confirm the impact of the $6 million milestone elimination on BioSig's projected cash flow and revenue recognition.
- Assess the financial implications of the royalty rate increase from 5% to 6% on future gross margins.
- Review the status of the Merimepodib clinical trials for COVID-19 to evaluate the likelihood of triggering the remaining milestones.